Cortellis Deals Landscape Q4 2016

During the 4th quarter of 2016, Cortellis Competitive Intelligence had 889 new deals added as part of its ongoing coverage of pharmaceutical licensing activity.

Read more >

The blockbuster drugs of 2016

After a record year for FDA drug approvals in 2015 with 45 NMEs gaining the regulatory go-ahead, the most since the all-time high of 53 set in 1996, 2016 has been a relative disappointment with only 16 NMEs approved at the time of writing.

Read more >

Competition doesn't always translate into cheaper drug prices

Countering the congressional clamor for more competition and negotiations to reduce prescription drug prices in the U.S., the biopharma industry is providing some context that shows competition among branded drugs and tough negotiations often translate into bigger rebates, not cheaper prices for patients.

Read more >

Big pharma, investors to academia: Our doors are open

Historically, the J.P. Morgan Healthcare Conference (JPM) wasn't exactly viewed as the ideal networking event for academic researchers still toiling in labs on discoveries that might, in the distant future, have therapeutic implications. That's changing, thanks to research models that accelerate the pace of early stage discovery along with a growing bent toward entrepreneurship among young scientists, a more proactive attitude among university technology transfer organizations and a transformation of JPM itself – or at least of San Francisco's Union Square milieu.

Read more >

China-U.S. biopharma players look on the bright side for 2017

The networking was lively and the outlook optimistic as the Chinese-American Bio/Pharmaceutical Society (CABS) conducted its second Investor Forum in conjunction with the 35th Annual J.P. Morgan (JPM) Healthcare Conference in San Francisco. With Chinese investments in U.S. businesses topping $15 billion last year – a record – the question on everyone's mind was whether direct investment in U.S. biotech and life sciences will continue to grow in the face of China's inward-facing currency pressures.

Read more >